Apolipoprotein D is a component of compact but not diffuse amyloid-beta plaques in Alzheimer's disease temporal cortex

2005 ◽  
Vol 20 (2) ◽  
pp. 574-582 ◽  
Author(s):  
Purnima P. Desai ◽  
Milos D. Ikonomovic ◽  
Eric E. Abrahamson ◽  
Ronald L. Hamilton ◽  
Barbara A. Isanski ◽  
...  
2016 ◽  
Vol 37 (6) ◽  
pp. 2062-2075 ◽  
Author(s):  
Pavitra Kannan ◽  
Martin Schain ◽  
Warren W Kretzschmar ◽  
Lora Weidner ◽  
Nicholas Mitsios ◽  
...  

Changes in P-glycoprotein and ABCG2 densities may play a role in amyloid-beta accumulation in Alzheimer’s disease. However, previous studies report conflicting results from different brain regions, without correcting for changes in vessel density. We developed an automated method to measure transporter density exclusively within the vascular space, thereby correcting for vessel density. We then examined variability in transporter density across brain regions, matter, and disease using two cohorts of post-mortem brains from Alzheimer’s disease patients and age-matched controls. Changes in transporter density were also investigated in capillaries near plaques and on the mRNA level. P-glycoprotein density varied with brain region and matter, whereas ABCG2 density varied with brain matter. In temporal cortex, P-glycoprotein density was 53% lower in Alzheimer’s disease samples than in controls, and was reduced by 35% in capillaries near plaque deposits within Alzheimer’s disease samples. ABCG2 density was unaffected in Alzheimer’s disease. No differences were detected at the transcript level. Our study indicates that region-specific changes in transporter densities can occur globally and locally near amyloid-beta deposits in Alzheimer’s disease, providing an explanation for conflicting results in the literature. When differences in region and matter are accounted for, changes in density can be reproducibly measured using our automated method.


2021 ◽  
Author(s):  
Martí Colom-Cadena ◽  
Jane Tulloch ◽  
Rosemary J Jackson ◽  
James H Catterson ◽  
Jamie Rose ◽  
...  

AbstractSynapse loss correlates with cognitive decline in Alzheimer’s disease (AD), and soluble amyloid beta (Aβ) is implicated in synaptic dysfunction and loss. An important knowledge gap is the lack of understanding of how synaptic accumulation of Aβ leads to synapse degeneration. In particular, there has been difficulty in determining whether there is a synaptic receptor that binds Aβ and mediates toxicity. While many candidate synaptic binding partners have been observed in model systems, their relevance to human AD brain remains unknown. This is in part due to methodological limitations preventing visualization of Aβ binding at individual synapses. To overcome this limitation, we combined two high resolution microscopy techniques: array tomography and Förster resonance energy transfer (FRET) to image over 1 million individual synaptic terminals in temporal cortex from AD (n=9) and age matched control cases (n=6). Within postsynaptic densities, Aβ generates a FRET signal with transmembrane protein 97 (TMEM97), recently discovered to be the Sigma-2 receptor, cellular prion protein, and postsynaptic density 95 (PSD95). TMEM97 is also present in a higher proportion of postsynapses in AD brain compared to control. Further, we inhibited Aβ-TMEM97 interaction in the APP/PS1+Tau mouse model of AD by treating with the Sigma-2 receptor complex allosteric antagonist CT1812 (n=20) or vehicle (n=20). CT1812 drug concentration correlated negatively with synaptic FRET signal between TMEM97 and Aβ. These data support a role for TMEM97 in the synaptic binding of Aβ in human Alzheimer’s disease brain where it may mediate synaptotoxicity.One Sentence SummaryIn Alzheimer’s disease, TMEM97 was present in a higher proportion of synapses and close enough to amyloid beta to be a potential synaptic binding partner.


2002 ◽  
Vol 38 ◽  
pp. 37-49 ◽  
Author(s):  
Janelle Nunan ◽  
David H Small

The proteolytic processing of the amyloid-beta protein precursor plays a key role in the development of Alzheimer's disease. Cleavage of the amyloid-beta protein precursor may occur via two pathways, both of which involve the action of proteases called secretases. One pathway, involving beta- and gamma-secretase, liberates amyloid-beta protein, a protein associated with the neurodegeneration seen in Alzheimer's disease. The alternative pathway, involving alpha-secretase, precludes amyloid-beta protein formation. In this review, we describe the progress that has been made in identifying the secretases and their potential as therapeutic targets in the treatment or prevention of Alzheimer's disease.


Sign in / Sign up

Export Citation Format

Share Document